INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

RGNXREGENXBIO Inc.

CIK 0001590877

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells2 / 0
Max Insider Score47
Connections7with evidence

RGNX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
17
MC
Malzahn CraigChief Technology Officer
RGNXREGENXBIO Inc.
Grant or award
A—
27.8K sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Ciongoli Gregory AustinDirector · Aug 27, 2026
  • ← Lobbied forevidence
    THEGROUP DC, LLCLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    DLA PIPER LLP (US)LDA Q2 2026 second quarter · Health issues, MED · Aug 26, 2026
9
MC
Malzahn CraigChief Technology Officer
RGNXREGENXBIO Inc.
Tax withholding
F
$2,181
234 sh
Sep 1, 2026
Sep 3, 2026
traded Sep 1, 2026
+2d
SEC FORM 4

Evidence

9
CA
Ciongoli Gregory AustinDirector
RGNXREGENXBIO Inc.
Grant or award
A—
69.6K sh
Aug 25, 2026Aug 27, 2026
traded Aug 25, 2026
+2dSEC FORM 4

Evidence

9
CA
Ciongoli Gregory AustinDirector
RGNXREGENXBIO Inc.
Grant or award
A—
15.4K sh
Aug 25, 2026Aug 27, 2026
traded Aug 25, 2026
+2dSEC FORM 4

Evidence

43
CA
Ciongoli Gregory AustinDirector
RGNXREGENXBIO Inc.
Open-market purchase
BUY$500K
53.4K sh
Aug 27, 2026Aug 27, 2026
traded Aug 27, 2026
+0dSEC FORM 4

Evidence

47
CA
Ciongoli Gregory AustinDirector
RGNXREGENXBIO Inc.
Open-market purchase
BUY$450K
49.2K sh
Aug 26, 2026Aug 27, 2026
traded Aug 26, 2026
+1dSEC FORM 4

Evidence

21
MC
Malzahn CraigChief Technology Officer
RGNXREGENXBIO Inc.
Grant or award
A—
65.8K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
MC
Malzahn CraigChief Technology Officer
RGNXREGENXBIO Inc.
Grant or award
A—
35.4K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

21
CM
Chan MitchellChief Financial Officer
RGNXREGENXBIO Inc.
Grant or award
A—
73.7K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
CM
Chan MitchellChief Financial Officer
RGNXREGENXBIO Inc.
Grant or award
A—
39.6K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

13
MC
Malzahn CraigChief Technology Officer
RGNXREGENXBIO Inc.
Tax withholding
F$18K
1,238 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    LMH STRATEGIC SOLUTIONSLDA Q2 2026 second quarter · Health issues, Pharmacy · Aug 26, 2026
  • ← Insider ofevidence
    Chan MitchellChief Financial Officer · Jan 8, 2026
  • ← Insider ofevidence
    Malzahn CraigChief Technology Officer · Jan 6, 2026

    • Lobbying

    $360K reported · de-duplicated
    2026 Q2 $180K via firms2026 Q1 $180K via firms
    • THEGROUP DC, LLC$60K2026 Q2 · posted Aug 26, 2026 · Health issues
    • DLA PIPER LLP (US)$60K2026 Q1 · posted Aug 26, 2026 · Health issues, MED
    • LMH STRATEGIC SOLUTIONS$60K2026 Q1 · posted Aug 26, 2026 · Pharmacy, Health issues
    • THEGROUP DC, LLC—2026 Q1 · posted Aug 26, 2026 · Health issues
    • LMH STRATEGIC SOLUTIONS$60K2026 Q2 · posted Aug 26, 2026 · Health issues, Pharmacy
    • DLA PIPER LLP (US)$60K2026 Q2 · posted Aug 26, 2026 · Health issues, MED
    • THEGROUP DC, LLC$60K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.